C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems etc.
Industry sector: Medical
Sector classification: Surgical & medical instruments
Deep Learning based analysis and prediction model for C.R. Bard, Inc. (BCR) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.
Model is in the production pipeline since Jan. 24, 2017.
Market data for BCR model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for BCR.
Model is being retrained on a regular basis.
| Float | 72M |
| P/E | 28.77 |
| Shares Outstanding | 73M |
| % Held by Insiders | 0.80% |
| % Held by Institutions | 79.11% |
| EPS (last reported FY) | $10.29 |
| EPS (last reported Q) | $3.02 |
| EPS, estimated (last reported Q) | $2.96 |
| Total revenues | $4 B |
| Net income | $1 B |